Current Issue – 2017 – Volume 20.2
Clinical Advances and Therapeutic Strategies for Patients with Epilepsy.
FDA APPROVED FOR INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS. In COMFORT-I* and COMFORT-II,† Jakafi® (ruxolitinib) significantly reduced spleen volume
compared with patients receiving placebo or best available therapy, respectively 1-3…
Updated Diagnostic and Individualized Treatment Strategies in the Management of Overactive Bladder
Chemotherapy-Induced Nausea and Vomiting (CINV): Perceptions, Mechanisms, and Treatment Guidelines